Mature B-Cell Neoplasm
NCI Definition: A neoplasm that arises from mature B-lymphocytes or plasma cells. Representative examples include mature B-cell non-Hodgkin lymphomas, chronic lymphocytic leukemia, hairy cell leukemia, and plasma cell neoplasms. 
Mature B-cell neoplasms most frequently harbor alterations in KMT2D, CREBBP, TP53, BCL2, and TNFRSF14 .
CREBBP Mutation, TP53 Mutation, KMT2D Mutation, TP53 Missense, and TP53 c.217-c.1178 Missense are the most common alterations in mature B-cell neoplasm .
There are 2 clinical trials for mature B-cell neoplasm, of which 1 is open and 1 is completed or closed. Of the trials that contain mature B-cell neoplasm as an inclusion criterion, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open).
Dihydroorotate dehydrogenase inhibitor and zanubrutinib are the most common interventions in mature B-cell neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.